SK288074B6 - Use of antibody which binds to AILIM in the treatment of immunological disorders - Google Patents
Use of antibody which binds to AILIM in the treatment of immunological disorders Download PDFInfo
- Publication number
- SK288074B6 SK288074B6 SK732-2001A SK7322001A SK288074B6 SK 288074 B6 SK288074 B6 SK 288074B6 SK 7322001 A SK7322001 A SK 7322001A SK 288074 B6 SK288074 B6 SK 288074B6
- Authority
- SK
- Slovakia
- Prior art keywords
- antibody
- cells
- ailim
- cell
- mouse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24267299 | 1999-08-30 | ||
JP2000254680 | 2000-08-24 | ||
PCT/JP2000/005868 WO2001015732A1 (fr) | 1999-08-30 | 2000-08-30 | Traitements de maladies immunitaires |
Publications (2)
Publication Number | Publication Date |
---|---|
SK7322001A3 SK7322001A3 (en) | 2001-12-03 |
SK288074B6 true SK288074B6 (sk) | 2013-05-03 |
Family
ID=26535864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK732-2001A SK288074B6 (sk) | 1999-08-30 | 2000-08-30 | Use of antibody which binds to AILIM in the treatment of immunological disorders |
Country Status (21)
Country | Link |
---|---|
US (2) | US7465445B2 (no) |
EP (1) | EP1125585B1 (no) |
JP (1) | JP3871503B2 (no) |
KR (2) | KR20040028960A (no) |
CN (2) | CN1359302A (no) |
AT (1) | ATE517925T1 (no) |
AU (1) | AU6865000A (no) |
BR (1) | BR0007047A (no) |
CA (1) | CA2348954C (no) |
CZ (1) | CZ304013B6 (no) |
HK (1) | HK1040489A1 (no) |
HU (1) | HU228575B1 (no) |
ID (1) | ID30042A (no) |
IL (2) | IL142691A0 (no) |
NO (2) | NO332264B1 (no) |
NZ (1) | NZ529577A (no) |
RU (1) | RU2203682C2 (no) |
SK (1) | SK288074B6 (no) |
TR (1) | TR200101205T1 (no) |
WO (1) | WO2001015732A1 (no) |
ZA (1) | ZA200103314B (no) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
SI2332978T1 (sl) | 1999-02-03 | 2014-08-29 | Amgen Inc. | Novi polipeptidi, vkljuäśeni v imunskem odgovoru |
US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
AU2002228610A8 (en) * | 2000-11-22 | 2012-02-02 | Univ Ohio State | Agents for blocking t cell mediated immune reactions |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
MX2009011996A (es) * | 2007-05-07 | 2010-04-21 | Medimmune Llc | Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica. |
JP6220774B2 (ja) | 2011-03-31 | 2017-10-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Icosに対する抗体及びその使用 |
DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
PL2717887T3 (pl) | 2011-06-09 | 2018-06-29 | University Of Florida Research Foundation, Inc. | Sposoby leczenia lub zapobiegania chorobie przeszczep przeciw gospodarzowi |
US9695247B2 (en) | 2012-09-03 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against ICOS for treating graft-versus-host disease |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
ES2863225T3 (es) | 2015-12-03 | 2021-10-11 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos purinos como moduladores del sting |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
SG11201808708RA (en) | 2016-04-07 | 2018-11-29 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
KR20230044038A (ko) | 2016-08-09 | 2023-03-31 | 키맵 리미티드 | 항-icos 항체 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
BR112019012901A2 (pt) | 2016-12-22 | 2020-01-07 | Daiichi Sankyo Company, Limited | Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula |
JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キナーゼ阻害剤としての複素環式アミド |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
WO2018225035A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
CN110869049A (zh) | 2017-06-09 | 2020-03-06 | 葛兰素史克知识产权开发有限公司 | 组合疗法 |
JP2020522556A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌を治療するためのicosアゴニストおよびox40アゴニストでの組み合わせ療法 |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
CN112469441A (zh) | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法 |
WO2019229614A1 (en) | 2018-05-31 | 2019-12-05 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer |
EP3806848A2 (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
US20210324081A1 (en) | 2018-10-22 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021046289A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
CA3155173A1 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
WO2021209356A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
EP4136113A1 (en) | 2020-04-14 | 2023-02-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
CN115461362A (zh) | 2020-04-14 | 2022-12-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法 |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
MX2023010067A (es) | 2021-03-02 | 2023-09-06 | Glaxosmithkline Ip Dev Ltd | Piridinas sustituidas como inhibidores de dnmt1. |
AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
JP2024511831A (ja) | 2021-03-31 | 2024-03-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質およびそれらの組み合わせ |
CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5521288A (en) | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
US5747461A (en) | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
ATE222774T1 (de) | 1996-01-23 | 2002-09-15 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
US5914112A (en) | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
TR199900596T2 (xx) | 1996-09-18 | 1999-06-21 | Zetesis S.P.A. | Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�. |
CA2270922A1 (en) | 1996-11-08 | 1998-05-14 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
CA2194814A1 (en) * | 1997-01-10 | 1998-07-10 | Terry L. Delovitch | Stimulation of protective t cells to prevent autoimmune disease |
WO1998037415A1 (en) | 1997-02-20 | 1998-08-27 | The Regents Of The University Of California | ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-vegf 항체 |
EA002549B1 (ru) * | 1997-05-17 | 2002-06-27 | Байоджен, Инк. | Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата |
DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
WO1999015553A2 (de) * | 1997-09-23 | 1999-04-01 | Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts | Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung |
JPH11228442A (ja) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
JP2000154151A (ja) | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
WO2000019988A1 (en) | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
SI2332978T1 (sl) | 1999-02-03 | 2014-08-29 | Amgen Inc. | Novi polipeptidi, vkljuäśeni v imunskem odgovoru |
PL360915A1 (en) | 1999-05-06 | 2004-09-20 | Genetics Institute, Llc | Use of soluble costimulatory molecules to enhance immune responses |
US6613327B1 (en) | 1999-07-28 | 2003-09-02 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
AU6458400A (en) | 1999-08-11 | 2001-03-13 | Isis Innovation Limited | Nucleic acid, polypeptides, assays, therapeutic methods and means |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
CA2383800A1 (en) | 1999-09-03 | 2001-03-15 | Human Genome Sciences Inc. | 52 human secreted proteins |
PT1218504E (pt) | 1999-09-21 | 2007-10-22 | Genetics Inst Llc | Novas moléculas gl50 e suas utilizações |
EP1224201A4 (en) | 1999-10-29 | 2005-03-02 | Human Genome Sciences Inc | 32 HUMAN SECRETED PROTEINS |
WO2001064704A1 (en) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | hB7-H2, A NOVEL CO-STIMULATORY MOLECULE |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
CA2429599A1 (en) | 2000-11-28 | 2002-06-06 | Amgen Inc. | Use of b7rp1 antagonists in ige-mediated disorders |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
2000
- 2000-08-29 JP JP2000258470A patent/JP3871503B2/ja not_active Expired - Fee Related
- 2000-08-30 AT AT00956800T patent/ATE517925T1/de not_active IP Right Cessation
- 2000-08-30 WO PCT/JP2000/005868 patent/WO2001015732A1/ja active IP Right Grant
- 2000-08-30 IL IL14269100A patent/IL142691A0/xx unknown
- 2000-08-30 CN CN00802420A patent/CN1359302A/zh active Pending
- 2000-08-30 NZ NZ529577A patent/NZ529577A/en not_active IP Right Cessation
- 2000-08-30 TR TR2001/01205T patent/TR200101205T1/xx unknown
- 2000-08-30 KR KR10-2004-7001435A patent/KR20040028960A/ko not_active Application Discontinuation
- 2000-08-30 CN CN2006101006481A patent/CN101028519B/zh not_active Expired - Fee Related
- 2000-08-30 SK SK732-2001A patent/SK288074B6/sk not_active IP Right Cessation
- 2000-08-30 HU HU0200994A patent/HU228575B1/hu not_active IP Right Cessation
- 2000-08-30 RU RU2001114516/14A patent/RU2203682C2/ru not_active IP Right Cessation
- 2000-08-30 CZ CZ20011720A patent/CZ304013B6/cs not_active IP Right Cessation
- 2000-08-30 AU AU68650/00A patent/AU6865000A/en not_active Abandoned
- 2000-08-30 CA CA2348954A patent/CA2348954C/en not_active Expired - Fee Related
- 2000-08-30 KR KR1020017005279A patent/KR100609441B1/ko not_active IP Right Cessation
- 2000-08-30 BR BR0007047-5A patent/BR0007047A/pt active Search and Examination
- 2000-08-30 ID IDW00200101165A patent/ID30042A/id unknown
- 2000-08-30 EP EP00956800A patent/EP1125585B1/en not_active Expired - Lifetime
-
2001
- 2001-04-19 IL IL142691A patent/IL142691A/en not_active IP Right Cessation
- 2001-04-24 ZA ZA200103314A patent/ZA200103314B/en unknown
- 2001-04-27 NO NO20012105A patent/NO332264B1/no not_active IP Right Cessation
-
2002
- 2002-02-22 HK HK02101307.4A patent/HK1040489A1/zh unknown
-
2003
- 2003-12-05 US US10/729,880 patent/US7465445B2/en not_active Expired - Fee Related
-
2008
- 2008-08-26 NO NO20083674A patent/NO20083674L/no not_active Application Discontinuation
- 2008-11-11 US US12/268,832 patent/US7998478B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK288074B6 (sk) | Use of antibody which binds to AILIM in the treatment of immunological disorders | |
US11414490B2 (en) | Regulatory T cell mediator proteins and uses thereof | |
JP3597140B2 (ja) | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 | |
RU2263512C2 (ru) | Средства, подавляющие отторжение трансплантата | |
CA2631015C (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
SK288036B6 (en) | Antibody that binds to AILIM, or a part of said antibody, for use in supressing, treating or preventing Crohn's disease | |
JPWO2002088186A1 (ja) | 抗cd40モノクローナル抗体 | |
RU2262511C2 (ru) | Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение | |
US20230015969A1 (en) | Regulatory t cell mediator proteins and uses thereof | |
AU2003262479B2 (en) | A Pharmaceutical Composition for Treating Immune Diseases | |
JP3543966B2 (ja) | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 | |
JP2005206478A (ja) | 樹状細胞膜分子−IgFc融合ポリペプチドまたはそれに対する抗体を含む医薬組成物 | |
JP4386776B2 (ja) | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 | |
MXPA01004315A (en) | Remedies for immunological diseases | |
JP4234992B2 (ja) | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20150830 |